IMPACT OF RITUXIMAB ON IMMUNE STATUS FOLLOWING THERAPY IN CHILDREN AND ADOLESCENTS WITH HIGH-RISK MATURE B-CELL NON-HODGKIN LYMPHOMA: RESULTS OF THE INTER-B-NHL RITUX 2010 TRIAL. (October 2022)